Kleiner Perkins leads $130M round in Coinbase founder’s anti-aging startup NewLimit

Quick Summary:

The startup is touting early successes in cell research related to the liver and immune system.

By pairing scaled genomics with frontier AI, NewLimit is accelerating advancements at a pace that the field has not seen before," said Ilya Fushman, a partner at Kleiner Perkins, in a statement.

Armstrong acknowledges these considerations will become more pressing if NewLimit succeeds as he hopes, but that the questions are bigger than what the startup can address.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Jeff John Roberts

Category: EconomyBusiness

Markets: United States

Topics: Venture Capital Fortune 500 Kleiner Perkins Longevity Coinbase

Source Website Secure: Yes (HTTPS)

News Sentiment: Positive

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-05-06 @ 15:00:05 (1 days ago)

News Timezone: GMT +8:00

News Source URL: fortune.com

Language: English

Article Length: 628 words

Reading Time: 4 minutes read

Sentences: 4 lines

Sentence Length: 157 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Fortune

News ID: 28441148

View Article Analysis

About Fortune

Main Topics: EconomyBusiness

Official Website: fortune.com

Update Frequency: 18 posts per day

Year Established: 1929

Headquarters: United States

News Last Updated: 8 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #95

Publisher Details

Frequently Asked Questions